LyckeJZetterbergH. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Rev Clin Immunol2017; 13(12): 1143–1153.
2.
FreedmanMSGnanapavanSBoothRA, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine2024; 101: 104970.
3.
NovakovaLZetterbergHSundströmP, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology2017; 89: 2230–2237.
4.
KuhleJPlavinaTBarroC, et al. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler2020; 26(13): 1691–1699.
5.
van LieropZYGJWesselsMHJLekrantyWML, et al. Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic. Mult Scler2024; 30(13): 1620–1629.
6.
BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol2022; 21(3): 246–257.
7.
JohnssonMStenbergYTFarmanHH, et al. Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study. Mult Scler2024; 30: 664–673.
8.
DisantoGBarroCBenkertP, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81: 857–870.
9.
BoseGHealyBCBarroC, et al. Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis. Mult Scler2023; 29(11–12): 1418–1427.
10.
FoxRJCreeBACde SèzeJ, et al. Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology2024; 102: e209357.
11.
BridelCVan WieringenWNZetterbergH, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol2019; 76: 1035–1048.
